

# Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V:

Epcoritamab (relapsed or refractory follicular lymphoma, at least 2 prior therapies);  
requirement of routine practice data collection and evaluations

of 6 March 2025

At their session on 6 March 2025, the Federal Joint Committee (G-BA) decided the following:

- I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient Epcoritamab for the treatment of  
"Adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy"  
is suspended.
- II. The resolution will enter into force on the day of its publication on the website of the G-BA on 6 March 2025.

The justification to this resolution will be published on the website of the G-BA at [www.g-ba.de](http://www.g-ba.de).

Berlin, 6 March 2025

Federal Joint Committee (G-BA)  
in accordance with Section 91 SGB V  
The Chair

Prof. Hecken